ADVANCES IN THE DIAGNOSIS AND TREATMENT OF THE RHEUMATIC DISEASES - May 2007
DESCRIPTION
This symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever-increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state-of-the-art diagnostic tools and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
TARGET AUDIENCE
This activity is intended for rheumatologists, internists, orthopedic surgeons and other allied health professionals.
OBJECTIVES
After attending this activity, the participant should be able to:
- discuss recent advances in the use of biologic agents in the treatment of rheumatoid arthritis
- understand the impact of biologic therapy in the treatment of psoriatic arthritis
- discuss new and emerging surgical and non-surgical options for managing osteoarthritis of the
spine
- understand major risk factors for the development and progression of osteoarthritis
- recognize the major ocular and renal manifestations of the rheumatic diseases
- learn how to manage patients with Juvenile Chronic Polyarthritis
- learn to distinguish statin-associated with inflammatory myopathy and appreciate how to manage
this condition
- recognize and distinguish non-sclerodermatous fibrosing skin diseases
- appreciate new advances in treatment for the systemic rheumatic diseases.
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. (Note: Credits available for each session range from 0.25 to 0.75)
CME APPROVAL DATES
Release Date: 10/1/2007
Expiration Date: 10/1/2010
POLICY ON SPEAKER AND PROVIDER DISCLOSURE
It is the policy of The Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.
NOTICE ABOUT OFF-LABEL USE PRESENTATIONS
The Johns Hopkins University School of Medicine/ Advances in the Diagnosis and Treatment of the Rheumatic Diseases may include presentations on drugs or devices, or use of drugs or devices, that have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
COPYRIGHT INFORMATION
All rights reserved. No part of this activity information may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
Advances in the Diagnosis and Treatment of the Rheumatic Diseases
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
NAME |
COMPANY |
| Susan Bartlett, PhD | Principal Investigator: NIH, Arthritis Foundation, ACR |
| Joan Bathon, MD | Consultant: Centocor Principal Investigator: Bristol-Myers Squibb, Roche, Amgen, Rinat, IDEC-Biogen |
| Michele Bellantoni, MD | Principal Investigator: Merck |
| Clifton O. Bingham III, MD | Principal Investigator: Amgen, Procter and Gamble, Merck, Wyeth, Novartis, Regeneron, McNeil, Pfizer, Winston Laboratories, Biotechnology General, Forest Laboratories, Merkele, United Therapeutics, Genentech, Xoma, Alexion, Bristol Myers Squibb, Biogen/IDEC, TAP Pharmaceuticals; Johns Hopkins Arthritis Center Website Director: Genentech, Bristol Myers Squibb, Amgen, Abbott; Consultant: Procter and Gamble, Healthonics, Merck, Novartis, Genentech, Amgen, Abbott, Aventis, Pfizer, Regeneron, McNeil |
| Bruce Bochner, MD | Consultant: Alba Therapeutics, Ception, Gerson-Lehrman Group, Glycomimetics, Inc., GlaxoSmithKline; Speaker Bureau: Genentech, Merck; Advisory Board: Genentech, GlaxoSmithKline; Editorial Council: Thomson, Up-To-Date; Research Support: NIH; Scientific Collaborations: GlaxoSmithKline, Human Genome Sciences; Other Financial: Scientific Advisory Board for Glycomimetics, Inc. |
| Christopher Ritchlin, MD | Principal Investigator:Centocor, Amgen; Consultant: Centocor, Amgen, Wyeth, Biogen, Abbott, Roche |
| Daniel Solomon, MD, MPH | Principal Investigator: Savient, Pfizer, Abbott |
| Michael Weinblatt, MD | Research Grants: Amgen, Abbott, BMS, Genentech, Millennium/Biogen, Arthritis Foundation, Oxford; Consultant: Abbott, Alza, Amgen, AstraZeneca, Biogen, Bioassets, BMS, Canfite, Celgene, Centocor, Critical Therapeutics, Enteremed, Human Genome, Genentech, Gilead, Lilly, Merrimack, Merck, Millennium, Novartis, Pfizer, Praecis, Propius, Rigel, Roche, Sanofi-Aventis, Serona, Scios, Synta, Trubion, Wyeth, UCB, VBL; Data Safety Monitoring Board: University of Alabama – Tear Study, Roche; Medical Education: Biocritique – Editor Rheumatology Forum, Remedica Medical Education – Co-Editor International Journal of Advances in Rheumatology, Chatham Institute – Co-Director RA education program RAPID, Harvard Medical School – Online CME program/Co-Director for case study in rheumatoid arthritis; Lecture Fees: Abbott, Amgen, Wyeth |
All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME |
PRODUCT |
| Clifton O. Bingham III, MD | Will discuss drugs in development for Osteoarthritis, potential additional therapeutic targets, and published experiences with Risedronate, Doxycycline and Diacherein in osteoarthritis. |
| Bruce Bochner, MD | Imatinib, mepolizumab |
| Francesco Boin, MD | IVIG |
| Lisa Christopher-Stine, MD, MPH | Coenzyme Q10, red yeast rice |
| Gary Hoffman, MD, MS | Every drug for vasculitis is unapproved. |
| Stuart Levine, MD | Pegylated Interferon/Ribavirin, Cellcept, and Rituximab for treatment of HCV-related cryoglobulinemic vasculitis |
| George B. Peters III, MD, MBA | Many immunosuppressors, all of which are not FDA labeled for ocular use. |
| Sangeeta Sule, MD | Infliximab, rituximab |
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
